| |
| |
|
| Insider
Information: |
Schenkein David P |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
168,823 |
|
|
Indirect Shares
|
417,826 |
|
|
| Direct
Value |
$4,779,911 |
|
|
|
Indirect Value
|
$13,063,921 |
|
|
| Total
Shares |
586,649 |
|
|
| Total
Value |
$17,843,832 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-3.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -16.7%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Agios Pharmaceuticals Inc |
AGIO |
Director |
2024-02-27 |
122,854 |
2024-02-27 |
349,854 |
Premium* |
|
|
Foundation Medicine, Inc. |
FMI |
Director |
2016-06-16 |
23,326 |
2016-06-16 |
10,508 |
Premium* |
|
|
Bluebird Bio, Inc. |
BLUE |
|
2020-06-18 |
6,832 |
2014-12-19 |
0 |
Premium* |
|
|
Denali Therapeutics Inc. |
DNLI |
Director |
2023-06-01 |
15,529 |
2023-06-01 |
57,464 |
Premium* |
|
|
Regeneron Pharmaceuticals Inc |
REGN |
Director |
2024-01-02 |
282 |
2023-09-08 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2024-02-27 |
4 |
S |
$33.60 |
$2,403,592 |
D/D |
(69,329) |
122,854 |
0 |
% |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2024-02-27 |
4 |
OE |
$31.64 |
$2,193,570 |
D/D |
69,329 |
180,325 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2024-02-26 |
4 |
S |
$33.19 |
$677,441 |
D/D |
(20,411) |
122,854 |
0 |
% |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2024-02-26 |
4 |
OE |
$31.64 |
$645,804 |
D/D |
20,411 |
143,265 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2024-02-23 |
4 |
OE |
$31.64 |
$1,510,209 |
D/D |
47,731 |
170,585 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2024-02-23 |
4 |
S |
$33.05 |
$1,577,510 |
D/D |
(47,731) |
122,854 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
42 |
282 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
Director |
– • – |
2023-09-08 |
4 |
A |
$0.00 |
$0 |
D/D |
240 |
240 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2023-06-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,975 |
122,854 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,216 |
15,529 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2023-04-03 |
4 |
AS |
$22.85 |
$373,895 |
D/D |
(16,363) |
117,879 |
0 |
% |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2023-04-03 |
4 |
OE |
$9.05 |
$148,085 |
D/D |
16,363 |
134,242 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2023-03-27 |
4 |
AS |
$22.15 |
$443,000 |
D/D |
(20,000) |
117,879 |
0 |
% |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2023-03-27 |
4 |
OE |
$9.05 |
$181,000 |
D/D |
20,000 |
137,879 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2023-02-27 |
4 |
OE |
$9.05 |
$181,000 |
D/D |
20,000 |
137,879 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2023-02-27 |
4 |
AS |
$25.37 |
$507,400 |
D/D |
(20,000) |
117,879 |
0 |
% |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2023-02-13 |
4 |
AS |
$28.62 |
$572,400 |
D/D |
(20,000) |
117,879 |
0 |
% |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2023-02-13 |
4 |
OE |
$9.05 |
$181,000 |
D/D |
20,000 |
137,879 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2023-01-30 |
4 |
AS |
$29.22 |
$586,578 |
D/D |
(20,000) |
117,879 |
0 |
% |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2023-01-30 |
4 |
OE |
$9.05 |
$181,000 |
D/D |
20,000 |
137,879 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2023-01-17 |
4 |
AS |
$28.82 |
$577,093 |
D/D |
(20,000) |
117,879 |
0 |
% |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2023-01-17 |
4 |
OE |
$9.05 |
$181,000 |
D/D |
20,000 |
137,879 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,986 |
11,313 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2022-05-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,585 |
117,879 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2022-02-22 |
4 |
D |
$29.08 |
$22,043 |
D/D |
(758) |
116,294 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
